Furthermore, about 60% of R/R ALL patients including B-ALL who received combination treatment of venetoclax with low-dose navitoclax, a Bcl-2/Bcl-XL inhibitor, reached complete remission in a phase 1 clinical trial (NCT03181126) [32]. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.